(3 years ago)
Commons ChamberThat is a good question, but such is the uncertainty around the variant and the rate at which it seems to be spreading that I am afraid that it is not possible to put a timeline on this action.
If we are to help reduce the chance of further variants emerging that will threaten the health of our citizens, we clearly need to accelerate vaccination programmes in other countries, particularly in the Commonwealth. Why are Ministers therefore so determined to use the World Trade Organisation ministerial meeting next week to block progress towards achieving—as South Africa and India want—a temporary waiver of intellectual property rules to help developing countries to develop their own vaccine manufacturing capacity?
The answer is that a temporary waiver of intellectual property for such purposes would be a huge step backwards. It would not help developing countries and it certainly would not help if we needed new vaccines, not just for covid-19 but for a future pandemic; the industry and businesses might step back and not bother developing if they believed that the intellectual property would always be waived in such circumstances. What is important, as I think the hon. Gentleman would agree, is that the companies developing these life-saving vaccines have an appropriate pricing and access policy for each country, so that vaccines are priced appropriately and accessibly for developing countries, and rich countries such as the UK, the US and others continue to do all they can through international vaccine donation programmes.